Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable Alzheimer disease~* Completed preceding double-blind study (3133L1-2203 US)~* MMSE score \> 9.~Exclusion Criteria:~* Significant brain MRI abnormalities~* Clinically important psychiatric symptoms~* History of stroke

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 5 mg/week

Based on this trial design, predict the completion outcome and termination type (if applicable).